M
Minhee Won
Researcher at Radiation Therapy Oncology Group
Publications - 63
Citations - 6389
Minhee Won is an academic researcher from Radiation Therapy Oncology Group. The author has contributed to research in topics: Temozolomide & Radiation therapy. The author has an hindex of 24, co-authored 58 publications receiving 5313 citations. Previous affiliations of Minhee Won include European Organisation for Research and Treatment of Cancer & American College of Radiology.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert,James J. Dignam,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Deborah T. Blumenthal,Michael A. Vogelbaum,Howard Colman,Arnab Chakravarti,Stephanie L. Pugh,Minhee Won,Robert Jeraj,Paul D. Brown,Kurt A. Jaeckle,David Schiff,Volker W. Stieber,David Brachman,Maria Werner-Wasik,Ivo W. Tremont-Lukats,Erik P. Sulman,Kenneth Aldape,Walter J. Curran,Minesh P. Mehta +22 more
TL;DR: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Journal ArticleDOI
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert,Meihua Wang,Kenneth Aldape,Roger Stupp,Monika E. Hegi,Kurt A. Jaeckle,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Minhee Won,Deborah T. Blumenthal,Anita Mahajan,Christopher J. Schultz,Sara Erridge,Brigitta G. Baumert,Kristen I. Hopkins,Tzahala Tzuk-Shina,Paul D. Brown,Arnab Chakravarti,Walter J. Curran,Minesh P. Mehta +20 more
TL;DR: This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation.
Journal ArticleDOI
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner,Edward G. Shaw,Stephanie L. Pugh,Arnab Chakravarti,Mark R. Gilbert,Geoffrey R. Barger,Stephen W. Coons,Peter Ricci,Dennis E. Bullard,Paul D. Brown,Keith J. Stelzer,David Brachman,John H. Suh,Christopher J. Schultz,Jean Paul Bahary,Barbara Fisher,Barbara Fisher,Harold Kim,Albert Murtha,Erica Hlavin Bell,Minhee Won,Minesh P. Mehta,Walter J. Curran +22 more
TL;DR: In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone.
Journal ArticleDOI
Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706
Colleen A. Lawton,Minhee Won,Miljenko V. Pilepich,Sucha O. Asbell,William U. Shipley,Gerald E. Hanks,James D. Cox,Carlos A. Perez,William T. Sause,S. Doggett,Philip Rubin +10 more
TL;DR: These data from two large multi-institutional trials represent a fair estimate of the actual incidence of major intestinal and urinary complications from external beam irradiation in the management of local and locoregional adenocarcinoma of the prostate.
Journal ArticleDOI
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Christian Grommes,Christian Grommes,Alessandro Pastore,Nicolaos Palaskas,Sarah S. Tang,Carl Campos,Derrek Schartz,Paolo Codega,Donna Nichol,Owen Clark,Wan-Ying Hsieh,Daniel Rohle,Marc K. Rosenblum,Agnes Viale,Viviane Tabar,Cameron Brennan,I. T. Gavrilovic,I. T. Gavrilovic,Thomas Kaley,Thomas Kaley,Craig Nolan,Craig Nolan,Antonio M. P. Omuro,Antonio M. P. Omuro,Elena Pentsova,Elena Pentsova,Alissa A. Thomas,Elina Tsyvkin,Elina Tsyvkin,Ariela Noy,Ariela Noy,M. Lia Palomba,M. Lia Palomba,Paul A. Hamlin,Paul A. Hamlin,Craig S. Sauter,Craig S. Sauter,Craig H. Moskowitz,Craig H. Moskowitz,Julia Wolfe,Ahmet Dogan,Minhee Won,Jon Glass,Scott Peak,Enrico C. Lallana,Vaios Hatzoglou,Anne S. Reiner,Philip H. Gutin,Jason T. Huse,Katherine S. Panageas,Thomas G. Graeber,Nikolaus Schultz,Lisa M. DeAngelis,Lisa M. DeAngelis,Ingo K. Mellinghoff,Ingo K. Mellinghoff +55 more
TL;DR: Ibrutinib has substantial activity in patients with relapsed or refractory B-cell lymphoma of the CNS, and combined inhibition of BTK and PI3K/mTOR may augment the ibrut inib response in CD79B-mutant human PCNSLs.